Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
77.29 ^USD	+2.24%		+20.65%	+0.17%

May. 02	UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating	MT
May. 02	Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85	MT

Bio-Techne Corporation Announces Dividend for the Quarter Ended June 30, 2022, Payable on August 29, 2022

August 04, 2022 at 06:30 am EDT

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2022. The quarterly dividend will be payable August 29, 2022, to all common shareholders of record on August 15, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Latest news about Bio-Techne Corporation

UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating	May. 02	MT
Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85	May. 02	MT
Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80	May. 02	MT
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept	May. 02	MT
Baird Adjusts Bio-Techne Price Target to $81 From $73	May. 02	MT
Equity Markets Mostly Fall After Fed Leaves Rate Unchanged	May. 01	MT
Equity Markets Mostly Fall After Fed Leaves Rate Unchanged	May. 01	MT
Top Midday Gainers	May. 01	MT
US Equity Indexes Mixed as Investors Look for Clarity in Fed's Policy Path in Presidential Election Year	May. 01	MT
US Equity Indexes Mixed Ahead of Fed Policy Statement, Views on Monetary Policy Path for 2024	May. 01	MT
Bio-Techne Shares Jump After Fiscal Q3 Beat	May. 01	MT
Deutsche Bank Adjusts Price Target on Bio-Techne to $84 From $82	May. 01	MT
Transcript : Bio-Techne Corporation, Q3 2024 Earnings Call, May 01, 2024	May. 01
Bio-Techne's Fiscal Q3 Adjusted Earnings Fall, Net Sales Rise	May. 01	MT
Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q3 Revenue $303.4M	May. 01	MT
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024	May. 01	CI
Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors	Apr. 30	CI
Bio-Techne to Enter Product Distribution Deal With Thermo Fisher Scientific	Apr. 29	MT
RBC Capital Adjusts Price Target on Bio-Techne to $71 From $79	Apr. 29	MT
Bio-Techne Corporation Announces New Distribution Agreement with Thermo Fisher Scientific	Apr. 29	CI
Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay	Apr. 26	CI
Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe	Apr. 23	MT
Deutsche Bank Adjusts Bio-Techne Price Target to $82 From $85	Apr. 18	MT
RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating	Apr. 08	MT
Bio-Techne Positioned for Growth Amid Biotech Funding Recovery, UBS Says	Mar. 28	MT

Chart Bio-Techne Corporation

Duration

Period

More charts

Company Profile

Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q4 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Bio-Techne Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

77.29 USD

Average target price

83.64 USD

Spread / Average Target

+8.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIO-TECHNE CORPORATION	+0.17%	12.15B
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B
UNITED THERAPEUTICS CORPORATION	+19.33%	11.64B

Other Biotechnology & Medical Research